Biomarin Pharmaceutical Inc (FRA:BM8)
€ 70 -4.12 (-5.56%) Market Cap: 13.55 Bil Enterprise Value: 13.60 Bil PE Ratio: 72.49 PB Ratio: 2.90 GF Score: 81/100

Biomarin Pharmaceutical Inc at JPMorgan Healthcare Conference Transcript

Jan 13, 2020 / 03:30PM GMT
Release Date Price: €82.51 (+0.01%)
Cory William Kasimov
JP Morgan Chase & Co, Research Division - Senior Biotechnology Analyst

All right. Good morning. Good morning, and Happy New Year, everyone. My name is Cory Kasimov. I'm the Senior Large-Cap Biotech analyst at JPMorgan. It's hard to believe we're back here already, but let me add my welcome to the 38th Annual Health Care Conference. With different biotech company kicking things off for us for the first time in a long time, and it's my pleasure to introduce BioMarin and the company's Chairman and CEO, J.J. Bienaimé. And please note that following J.J.'s presentation, there's a breakout just across the hall in the Georgian room. So with that, turn it over to J.J.

Jean;Jacques BienaimÃ;BioMarin Pharmaceutical Inc.;Chairman;CEO

©,-&

Thank you, Cory. Good morning, everybody. Bright and early here. This is the earliest time I ever presented at JPMorgan, but that's fine. So we're very excited about being here today.

As usual, this presentation will contain forward-looking

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot